Cholecystokinin in pig plasma: release of components devoid of a bioactive COOH-terminus
- PMID: 2912150
- DOI: 10.1152/ajpgi.1989.256.1.G53
Cholecystokinin in pig plasma: release of components devoid of a bioactive COOH-terminus
Abstract
Using radioimmunoassays specific for different sequences of cholecystokinin (CCK), we studied the intestinal release of CCK in pigs. After stimulation by intraduodenal infusion of HCl, plasma CCK concentrations, measured with an antiserum specific for the sulfated, bioactive sequence of CCK, increased from 1.4 +/- 0.7 to 42.7 +/- 11.7 pM in portal plasma and from 0.5 +/- 0.3 to 12.3 +/- 1.5 pM in peripheral plasma. The concentrations measured with an antiserum specific for the NH2-terminal sequence 5-10 of CCK-33 were considerably higher, increasing from 64 +/- 17 to 139 +/- 14 pM in portal plasma and from 69 +/- 7 to 102 +/- 9 pM in peripheral plasma. Chromatography suggested that the NH2-terminal immunoreactivity consisted of large CCK fragments devoid of the bioactive COOH-terminal octapeptide, i.e., desocta and/or desnona CCK-58, CCK-39, and CCK-33. The bioactive forms in both portal and peripheral plasma comprised CCK-58-, CCK-33-, CCK-22-, CCK-12-, and CCK-8-like forms. Generally, the CCK-22-like component predominanated, but although CCK-8 was more abundant than CCK-33 in portal plasma, these forms occurred in equal amounts in peripheral plasma. Large amounts of NH2-terminal immunoreactivity were also found in the venous effluent of the isolated perfused duodenum after stimulation with gastrin-releasing peptide; the venous perfusate contained mainly CCK-22- and CCK-8-like material, which together constituted greater than 80% of the bioactive CCK components. Both duodenal and jejunal mucosa contained components resembling NH2-terminal fragments as well as large amounts of intact CCK-58 and CCK-33.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
The molecular nature of vascularly released cholecystokinin from the isolated perfused porcine duodenum.Regul Pept. 1982 Jan;3(1):15-28. doi: 10.1016/0167-0115(82)90003-9. Regul Pept. 1982. PMID: 7054860
-
The molecular nature of cholecystokinin in plasma. An in vivo immunosorption study in rabbits.Scand J Gastroenterol. 1994 Feb;29(2):110-21. doi: 10.3109/00365529409090448. Scand J Gastroenterol. 1994. PMID: 8171278
-
Cholecystokinin-58 is the major circulating form of cholecystokinin in canine blood.J Biol Chem. 1987 Jan 5;262(1):214-7. J Biol Chem. 1987. PMID: 3793725
-
Plasma cholecystokinin and its precursors in hepatic cirrhosis.J Hepatol. 1997 Aug;27(2):299-305. doi: 10.1016/s0168-8278(97)80175-4. J Hepatol. 1997. PMID: 9288604 Review.
-
The biology of cholecystokinin and gastrin peptides.Curr Top Med Chem. 2007;7(12):1154-65. doi: 10.2174/156802607780960483. Curr Top Med Chem. 2007. PMID: 17584137 Review.
Cited by
-
Role of gastrointestinal hormones in feeding behavior and obesity treatment.J Gastroenterol. 2016 Feb;51(2):93-103. doi: 10.1007/s00535-015-1118-4. Epub 2015 Sep 7. J Gastroenterol. 2016. PMID: 26346735 Review.
-
Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes.Diabetologia. 2012 Oct;55(10):2747-2758. doi: 10.1007/s00125-012-2654-6. Epub 2012 Jul 20. Diabetologia. 2012. PMID: 22814764
-
Systemic cholecystokinin amplifies vago-vagal reflex responses recorded in vagal motor neurones.J Physiol. 2012 Feb 1;590(3):631-46. doi: 10.1113/jphysiol.2011.224477. Epub 2011 Dec 12. J Physiol. 2012. PMID: 22155934 Free PMC article.
-
Cholecystokinin: Clinical aspects of the new biology.J Intern Med. 2025 Sep;298(3):251-267. doi: 10.1111/joim.20110. Epub 2025 Jun 25. J Intern Med. 2025. PMID: 40557463 Free PMC article. Review.
-
Mechanisms of action of CCK to activate central vagal afferent terminals.Peptides. 2008 Oct;29(10):1716-25. doi: 10.1016/j.peptides.2008.06.023. Epub 2008 Jul 4. Peptides. 2008. PMID: 18655818 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources